|
US6150415A
(en)
*
|
1996-08-13 |
2000-11-21 |
The Regents Of The University Of California |
Epoxide hydrolase complexes and methods therewith
|
|
US8815951B2
(en)
*
|
1996-08-13 |
2014-08-26 |
The Regents Of The University Of California |
Inhibitors of epoxide hydrolases for the treatment of inflammation
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP2298311B1
(en)
*
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
|
US6831099B1
(en)
*
|
1999-05-12 |
2004-12-14 |
Yale University |
Enzyme inhibition
|
|
ES2165768B1
(es)
|
1999-07-14 |
2003-04-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
US6562563B1
(en)
*
|
1999-11-03 |
2003-05-13 |
Mitokor |
Compositions and mehtods for determining interactions of mitochondrial components, and for identifying agents that alter such interactions
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
WO2002082082A2
(en)
*
|
2001-04-09 |
2002-10-17 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Fluorescence polarization assay
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
US6756210B2
(en)
*
|
2001-05-29 |
2004-06-29 |
The Regents Of The University Of California |
Linoleic acid diol and glucuronide conjugate levels as diagnostic markers of disorders of abnormal regulation of cytochrome P450 metabolism of unsaturated fatty acids
|
|
CA2456229A1
(en)
*
|
2001-08-03 |
2003-02-13 |
Diversa Corporation |
Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
|
|
US6943001B2
(en)
*
|
2001-08-03 |
2005-09-13 |
Diversa Corporation |
Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
|
|
US20030139469A1
(en)
*
|
2002-01-23 |
2003-07-24 |
The Regents Of The University Of California |
Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
|
|
ATE529406T1
(de)
|
2002-02-11 |
2011-11-15 |
Bayer Healthcare Llc |
Aryl-harnstoffe als kinase inhibitoren
|
|
WO2003068229A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
|
DK1478358T3
(da)
|
2002-02-11 |
2013-10-07 |
Bayer Healthcare Llc |
Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
|
|
GB0214342D0
(en)
*
|
2002-06-21 |
2002-07-31 |
Givaudan Sa |
Insect repellents
|
|
EP1558591B1
(en)
|
2002-10-07 |
2014-05-07 |
The Regents of The University of California |
Modulation of anxiety through blockade of anandamide hydrolysis
|
|
UY28213A1
(es)
|
2003-02-28 |
2004-09-30 |
Bayer Pharmaceuticals Corp |
Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
|
|
WO2004089296A2
(en)
|
2003-04-03 |
2004-10-21 |
The Regents Of The University Of California |
Improved inhibitors for the soluble epoxide hydrolase
|
|
US20050164951A1
(en)
*
|
2003-04-03 |
2005-07-28 |
The Regents Of The University Of California |
Inhibitors for the soluble epoxide hydrolase
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
PL1663978T3
(pl)
|
2003-07-23 |
2008-04-30 |
Bayer Healthcare Llc |
Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
|
|
EP1765311A4
(en)
*
|
2004-03-16 |
2009-04-29 |
Univ California |
REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
|
|
ES2257152B1
(es)
*
|
2004-05-31 |
2007-07-01 |
Laboratorios Almirall S.A. |
Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
|
|
WO2006045119A2
(en)
|
2004-10-20 |
2006-04-27 |
The Regents Of The University Of California |
Improved inhibitors for the soluble epoxide hydrolase
|
|
WO2006121684A2
(en)
*
|
2005-05-06 |
2006-11-16 |
Boehringer Ingelheim International, Gmbh |
Acyl hydrazones for treating cardiovascular diseases
|
|
US20060276515A1
(en)
*
|
2005-05-06 |
2006-12-07 |
Cywin Charles L |
Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same
|
|
CA2619768A1
(en)
*
|
2005-08-19 |
2007-02-22 |
The Regents Of The University Of California |
Use of seh inhibitors as analgesics
|
|
WO2007044491A1
(en)
*
|
2005-10-07 |
2007-04-19 |
Boehringer Ingelheim International Gmbh |
N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors
|
|
EP2623113B1
(en)
|
2005-11-09 |
2017-05-31 |
Onyx Therapeutics, Inc. |
Compound for enzyme inhibition
|
|
CA2636601C
(en)
*
|
2006-01-13 |
2019-03-19 |
Cosmas Therapeutics Development Inc. |
Novel melatonin ligands having antidepressant activity as well as sleep inducing properties
|
|
WO2007106705A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Boehringer Ingelheim International Gmbh |
Soluble epoxide hydrolase inhibitors and methods of using same
|
|
AR059826A1
(es)
*
|
2006-03-13 |
2008-04-30 |
Univ California |
Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
|
|
NZ597545A
(en)
|
2006-06-19 |
2013-07-26 |
Proteolix Inc |
Peptide epoxyketones for proteasome inhibition
|
|
EP2124928A4
(en)
*
|
2006-12-15 |
2011-01-05 |
Univ California |
USE OF CIS EPOXY EICOSATRIC ACIDS AND INHIBITORS OF SOLUBLE EPOXY HYDROLASE FOR THE TREATMENT OF DISEASES CAUSED BY PBR, CB2 AND NK
|
|
EP2091542A1
(en)
*
|
2006-12-18 |
2009-08-26 |
F. Hoffmann-Roche AG |
Novel use of inhibitors of soluble epoxide hydrolase
|
|
WO2009011872A1
(en)
*
|
2007-07-17 |
2009-01-22 |
Merck & Co., Inc. |
Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
|
|
WO2009020960A1
(en)
|
2007-08-06 |
2009-02-12 |
The Regents Of The University Of California |
Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase
|
|
CA2701778C
(en)
|
2007-10-04 |
2018-09-11 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
|
WO2009111207A1
(en)
*
|
2008-03-04 |
2009-09-11 |
Merck & Co., Inc. |
Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
|
|
EP2100598A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
EP2100599A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
JP5675629B2
(ja)
|
2008-10-21 |
2015-02-25 |
オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
ペプチドエポキシケトンを用いた併用療法
|
|
WO2010096722A1
(en)
|
2009-02-20 |
2010-08-26 |
Takeda Pharmaceutical Company Limited |
3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
|
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
|
WO2011060179A1
(en)
|
2009-11-13 |
2011-05-19 |
Onyx Therapeutics, Inc |
Use of peptide epoxyketones for metastasis suppression
|
|
EP2528604B1
(en)
|
2010-01-29 |
2017-11-22 |
The Regents of the University of California |
Acyl piperidine inhibitors of soluble epoxide hydrolase
|
|
AU2011223795B2
(en)
|
2010-03-01 |
2015-11-05 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
|
CA2795559A1
(en)
|
2010-04-07 |
2011-11-03 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
|
EP2389922A1
(en)
|
2010-05-25 |
2011-11-30 |
Symrise AG |
Cyclohexyl carbamate compounds as anti-ageing actives
|
|
US9029401B2
(en)
|
2011-02-14 |
2015-05-12 |
The Regents Of The University Of California |
Sorafenib derivatives as sEH inhibitors
|
|
EP2510928A1
(en)
|
2011-04-15 |
2012-10-17 |
Almirall, S.A. |
Aclidinium for use in improving the quality of sleep in respiratory patients
|
|
US9034903B2
(en)
|
2012-02-01 |
2015-05-19 |
The Regents Of The University Of California |
Acyl piperidine inhibitors of soluble epoxide hydrolase
|
|
WO2013138118A1
(en)
|
2012-03-14 |
2013-09-19 |
The Regents Of The University Of California |
Treatment of inflammatory disorders in non-human mammals
|
|
WO2014011695A2
(en)
|
2012-07-09 |
2014-01-16 |
Onyx Therapeutics, Inc. |
Prodrugs of peptide epoxy ketone protease inhibitors
|
|
US10813894B2
(en)
|
2015-02-20 |
2020-10-27 |
The Regents Of The University Of California |
Methods of inhibiting pain
|
|
EP3463470A1
(en)
|
2016-05-25 |
2019-04-10 |
Johann Wolfgang Goethe-Universität Frankfurt am Main |
Treatment and diagnosis of non-proliferative diabetic retinopathy
|
|
US20210378995A1
(en)
|
2018-10-10 |
2021-12-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction
|
|
CA3118924A1
(en)
|
2018-11-09 |
2020-05-14 |
Ginkgo Bioworks, Inc. |
Biosynthesis of mogrosides
|